LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious d...
LakeShore Biopharma Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company
BEIJING, Aug. 18, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious d...
LakeShore Biopharma Announces US$15 Million Private Placement Financing
BEIJING, July 8, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) (the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today ...
LakeShore Biopharma Announces the Official Launch of a Novel Packaging Solution for YSJA? Rabies Vaccine (Vero Cell)
Revolutionizing Vaccination Safety with Needle-Free Reconstitution Technology BEIJING, April 23, 2025 /PRNewswire/ -- On April 18, 2025,?LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company") successfully held the 2025 CSO ("Contract Sales Organization")?Annual Meeti...
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
* Achieved total revenue of RMB 371.9 million, reflecting a growth of 36.2% YoY * Achieved gross profit of?RMB 307.3 million, a growth of 39.1% YoY * Gross margin increased to 82.6% from 80.9% in the same period of FY2024 * Total operating expenses decreased to?RMB 276.4 million, down 31.6%...
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
GAITHERSBURG, Md., Oct. 29, 2024 /PRNewswire/ --?LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for i...
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
GAITHERSBURG, Md., Oct. 25, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for i...
LakeShore Biopharma Provides Fiscal Half Year 2025 Financial Guidance and Reaffirms Fiscal Year 2025 Financial Guidance
GAITHERSBURG, Md., Oct. 8, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for in...
LakeShore Biopharma Announces Results of Extraordinary General Meeting on Share Consolidation
GAITHERSBURG, Md., Sept. 27, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024
GAITHERSBURG, Md., Sept. 10, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...
LakeShore Biopharma Announces Leadership Transitions
GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...
LakeShore Biopharma Announces Leadership Transitions
GAITHERSBURG, Md., Sept. 4, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for ...
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024
Gross margin increased to 79.5%; product pipeline continues to advance Company anticipates double-digit year-over-year revenue growth and bottom line breakeven for Fiscal Year 2025 GAITHERSBURG, Md., Aug. 15, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd. (Nasdaq: LSB) ("LakeShore Biopharma"...
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition
GAITHERSBURG, Md., July 5, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for in...
